GSK GSK plc

By Tapan Panchal

LONDON--GlaxoSmithKline PLC (GSK.LN) said Thursday it has embarked on a new study to evaluate the effects of losmapimod medicine in patients with acute coronary syndrome.

The syndrome is a term for various heart conditions including heart attacks, where there is an abrupt reduction of blood flow to the heart through the coronary arteries.

The pharmaceutical company said that it has started a phase III study to assess whether losmapimod can reduce the risk of a subsequent cardiac events when administered orally twice a day for a period of three months.

Shares of GSK at 1356 GMT were up 0.03% at 1582 pence, valuing the company at 76.78 billion pounds (128.49 billion).

Write to Tapan Panchal at tapan.panchal@wsj.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires